Mirador Capital Partners’s Avidity Biosciences RNAM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-62,737
| Closed | -$4.53M | – | 214 |
|
|
2025
Q4 | $4.53M | Sell |
62,737
-1,318
| -2% | -$85.1K | 0.62% | 43 |
|
|
2025
Q3 | $2.79M | Buy |
64,055
+22,666
| +55% | +$916K | 0.4% | 56 |
|
|
2025
Q2 | $1.18M | Buy |
41,389
+13,189
| +47% | +$393K | 0.19% | 84 |
|
|
2025
Q1 | $832K | Buy |
28,200
+2,569
| +10% | +$80K | 0.15% | 104 |
|
|
2024
Q4 | $745K | Sell |
25,631
-4,867
| -16% | -$203K | 0.14% | 107 |
|
|
2024
Q3 | $1.4M | Sell |
30,498
-10,415
| -25% | -$452K | 0.25% | 64 |
|
|
2024
Q2 | $1.67M | Sell |
40,913
-6,160
| -13% | -$177K | 0.31% | 53 |
|
|
2024
Q1 | $1.2M | Sell |
47,073
-5,488
| -10% | -$86K | 0.23% | 71 |
|
|
2023
Q4 | $476K | Buy |
52,561
+36,195
| +221% | +$242K | 0.1% | 122 |
|
|
2023
Q3 | $104K | Sell |
16,366
-53,395
| -77% | -$460K | 0.02% | 179 |
|
|
2023
Q2 | $774K | Buy |
69,761
+7,250
| +12% | +$90.9K | 0.18% | 94 |
|
|
2023
Q1 | $960K | Buy |
62,511
+28,007
| +81% | +$616K | 0.23% | 73 |
|
|
2022
Q4 | $766K | Buy |
34,504
+384
| +1% | +$5.72K | 0.18% | 85 |
|
|
2022
Q3 | $557K | Sell |
34,120
-663
| -2% | -$12.7K | 0.13% | 103 |
|
|
2022
Q2 | $505K | Buy |
34,783
+967
| +3% | +$14.4K | 0.12% | 120 |
|
|
2022
Q1 | $625K | Buy |
33,816
+3,115
| +10% | +$52.9K | 0.13% | 121 |
|
|
2021
Q4 | $730K | Buy |
30,701
+9,980
| +48% | +$238K | 0.15% | 109 |
|
|
2021
Q3 | $510K | Buy |
+20,721
| New | +$450K | 0.12% | 133 |
|
Other funds holding RNAM
Mirador Capital Partners's RNAM Position: Q1 2026 in Review
Mirador Capital Partners sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 62,737 shares — an estimated $4.53M sold.
Mirador Capital Partners first reported a position in RNAM in Q3 2021 and held it in 18 quarters. The position peaked at $4.53M in Q4 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.
- Mirador Capital Partners reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
- Mirador Capital Partners sold 62,737 Avidity Biosciences shares in Q1 2026, an estimated $4.53M.
- Mirador Capital Partners first reported a position in Avidity Biosciences in Q3 2021 and held it in 18 quarters.
- Mirador Capital Partners's Avidity Biosciences position peaked at $4.53M in Q4 2025.
- 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.
Based on Mirador Capital Partners's 13F filing for Q1 2026, filed 8 Apr 2026.